Wanbury Limited has announced the appointment of Pradeep Patni as the Chief Executive Officer (CEO) of its India Formulation Business.

Patni brings over 25 years of distinguished experience in the pharmaceutical industry, having most recently served as CEO at Akumentis. During his 4 - year tenure (FY21-24) at Akumentis, Patni, along with the leadership team, drove remarkable growth in sales, which increased by 1.7 times from Rs. 233 crore in FY21 to Rs. 398 crore in FY24. Additionally, the EBITDA margin improved significantly, rising from 4% in FY21 to 21 % in FY24.

An MBA from IIM Bangalore, he has a rich background in managing independent business units within leading multinational pharmaceutical corporations. His broad expertise spans both patented and generic molecules, as well as bio-therapeutics, enabling him to navigate diverse markets and portfolios effectively. Throughout his career, Mr. Patni has consistently delivered on organizational objectives.

Patni, began his career at Ranbaxy Labs and has since built a successful professional trajectory in the pharmaceutical industry, having worked with companies such as Janssen (10 years), Pfizer Ltd. (6 years), Abbott Healthcare (6 years) and Micro Labs.